Pyxis Oncology Inc Dossier - Source-backed chat

Pyxis Oncology Inc

PYXSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.19

Intrinsic Value $2.45median of 2 methodsbased on filings through 30 Jun 2026

Market Price $2.19Price as of 1 Oct 2026

Near fair valueIntrinsic value is 12% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $182.7M

Enterprise Value $163.8M

Shares Outstanding 83.4M diluted

Next Earnings Date2 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Pyxis Oncology is a high-risk, high-reward clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers. The investment thesis centers on its lead candidate, micvotabart pelidotin (MICVO), a first-in-concept ADC targeting extradomain-B of fibronectin (EDB+FN) in the tumor extracellular matrix. With key clinical readouts for both monotherapy (mid-2026) and combination therapy (2H 2026) in head and neck squamous cell carcinoma (R/M HNSCC) imminent, the stock presents a highly asymmetric catalyst setup. While cash runway constraints into Q4 2026 pose near-term financing risks, positive clinical data could significantly de-risk the platform, attract big pharma partnerships, and drive substantial valuation upside.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$6.75

High · most bullish analyst$8.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.0020%

The dose cap fails to sufficiently improve the safety profile, or the efficacy drops significantly below the historical 26% ORR, rendering MICVO uncompetitive in the crowded HNSCC landscape. With cash running out in Q4 2026 and no positive clinical catalysts to leverage, the company is forced to execute a highly dilutive down-round financing or halt development of its lead asset, causing severe capital destruction.

Base CaseCentral scenario

$6.7555%

Matches the consensus mean

MICVO monotherapy data confirms a manageable safety profile under the dose cap with stable efficacy, and the combination data shows incremental benefit over pembrolizumab monotherapy. The company successfully leverages these results to secure a dilutive or non-dilutive financing round/partnership in late 2026, extending its cash runway into late 2027 and allowing advancement into Phase 2 trials. The stock trades up toward the consensus analyst target.

Bull CaseUpside scenario

$9.0025%

The mid-2026 monotherapy data demonstrates that the implemented dose cap (5.4 mg/kg) successfully resolves previous safety/tolerability concerns (Grade 3 adverse events in high body weight patients) while maintaining or improving the historical ~26% overall response rate (ORR). Furthermore, the 2H 2026 combination data with pembrolizumab shows strong synergistic efficacy in 1L R/M HNSCC. This dual validation triggers a major licensing partnership or acquisition offer, completely resolving cash runway concerns and driving the stock toward the high-end analyst target.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-concept ADC targeting EDB+FN, a highly selective tumor microenvironment antigen largely absent in healthy adult tissues.
Fast Track Designation granted by the FDA for MICVO in 2L+ R/M HNSCC, accelerating potential regulatory pathways.
Imminent near-term clinical catalysts in mid-2026 and 2H 2026 that will rapidly validate or invalidate the therapeutic platform.
Preclinical synergy demonstrated with pembrolizumab, supporting a strong biological rationale for the ongoing 1L combination trial.

Key Investment Risks

Extremely tight cash runway extending only into Q4 2026, presenting high near-term financing and dilution risk.
Historical safety concerns (Grade 3 adverse events and discontinuations in higher body weight patients) that the newly implemented dose cap must successfully resolve.
Highly competitive oncology landscape with established and emerging ADC players targeting solid tumors.
Interim leadership state following the transition to Interim CEO Thomas Civik, introducing execution and strategic continuity risks.

Thesis Invalidation Triggers

Failure of the dose cap to reduce Grade 3 adverse events or maintain therapeutic efficacy in the mid-2026 monotherapy readout.
Inability to secure additional funding or a strategic partnership before Q4 2026, leading to a severe liquidity crisis.
Clinical hold or major regulatory delays imposed by the FDA due to safety signals in the combination or monotherapy trials.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.